For more than 25 years, Centocor has been a leader in the field of biomedicines. Through the dynamic science of biotechnology, the company continues to seek innovative ways to treat cancer and immune-mediated inflammatory disorders, such as rheumatoid arthritis and plaque psoriasis.
Centocor's work has revolutionized the science of immunology. Centocor pioneered monoclonal antibody technology, a cutting-edge approach that launched a new generation of products to treat immune-related diseases.
As profound as these breakthroughs have been, they are just the beginning. Centocor's ultimate goal: develop cures for immune-related diseases.
To learn more about CENTOCOR, please visit the company's website at www.centocor.com